Logo

XRTX

XORTX Therapeutics Inc.

XRTX

XORTX Therapeutics Inc. • NASDAQ
$0.65 ▲ 4.08% (+0.03)
Market Cap $2.46 M
52w High $1.79
52w Low $0.52
Dividend Yield 0%
P/E -1.62
Volume 69.58K
Outstanding Shares 3.79M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $0 $679.197K ▼ $-642.268K ▲ 0% $-0.13 ▲ $-613.209K ▲
Q2-2025 $0 $876.523K ▼ $-729.525K ▼ 0% $-0.19 $-701.441K ▼
Q1-2025 $0 $934.638K ▲ $-696.561K ▼ 0% $-0.19 ▼ $-670.655K ▼
Q4-2024 $0 $617.196K ▼ $119.076K ▲ 0% $0.039 ▲ $144.482K ▲
Q3-2024 $0 $855.627K $-591.732K 0% $-0.2 $-565.575K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.664M ▲ $3.917M ▲ $1.165M ▲ $2.746M ▲
Q2-2025 $1.063M ▼ $2.742M ▼ $711.455K ▼ $2.031M ▼
Q1-2025 $1.895M ▼ $3.499M ▼ $757.35K ▼ $2.741M ▼
Q4-2024 $2.472M ▲ $4.092M ▲ $757.539K ▼ $3.335M ▲
Q3-2024 $2.301M $3.85M $1.717M $2.134M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-642.268K ▲ $-620.871K ▲ $-5.31K ▲ $773.744K ▲ $126.908K ▲ $-620.868K ▲
Q2-2025 $-717.7K ▼ $-793.519K ▼ $-21.825K ▼ $-43.444K ▼ $-831.761K ▼ $-815.344K ▼
Q1-2025 $-698.673K ▼ $-643.73K ▲ $-3.385K ▲ $67.577K ▼ $-578.411K ▼ $-647.115K ▲
Q4-2024 $122.535K ▲ $-886.408K ▼ $-4.036K ▲ $1.107M ▲ $172.902K ▲ $-890.444K ▼
Q3-2024 $-587.011K $-751.851K $-23.181K $-22.238K $-777.725K $-775.032K

Five-Year Company Overview

Income Statement

Income Statement XORTX is still a pre‑revenue biotech company. It has not yet generated product sales and has been operating at a loss, which is typical for a small clinical‑stage drug developer. Reported earnings per share have been negative each year, reflecting ongoing spending on research, regulatory work, and overhead with no offsetting revenue. For now, the story is entirely about future potential rather than current profitability.

Balance Sheet

Balance Sheet The balance sheet is very small and light. The company shows only modest assets and cash, no meaningful debt, and a thin layer of equity. This suggests limited financial cushion and a strong dependence on future fundraising to support trials and operations. The series of reverse stock splits also indicates past pressure on the share price and efforts to maintain listing standards, which often go hand‑in‑hand with equity dilution over time.

Cash Flow

Cash Flow Cash flow is negative from operations, again consistent with a pre‑revenue biotech funding research and corporate costs. There is essentially no spending on physical assets, so nearly all cash use appears to be for people, trials, and development work. With no internal cash generation, the company’s ability to continue its programs depends on raising additional capital, securing grants, or forming partnerships. The absolute burn looks modest, but relative to the company’s size, it is significant.

Competitive Edge

Competitive Edge XORTX is trying to carve out a focused niche in kidney disease and gout by targeting high uric acid levels and related metabolism. Its key potential advantages are a proprietary oral oxypurinol formulation (XORLO), patent protection, and orphan drug status in a rare kidney disease, which together can create regulatory and commercial exclusivity. The company concentrates on underserved patient groups, such as those who cannot tolerate standard gout drugs or who have limited options for polycystic kidney disease. On the other hand, XORTX is small and up against large pharmaceutical players and competing pipelines, so success likely hinges on clear clinical data, regulatory wins, and possibly strong partners.

Innovation and R&D

Innovation and R&D Innovation is the core asset here. XORLO, the improved oxypurinol formulation, underpins multiple programs: a lead gout drug for allopurinol‑intolerant patients, a late‑stage program for polycystic kidney disease with orphan designation, and earlier‑stage work in diabetic kidney disease and acute kidney injury. The scientific thesis—reducing uric acid to slow disease progression—is well grounded but still needs to be proven in larger, pivotal trials. The R&D strategy is relatively focused, which is a strength, but it also concentrates risk in a small number of related programs and mechanisms.

Summary

XORTX is a tiny, high‑risk, high‑uncertainty, pre‑revenue biotech built around one core technology platform aimed at gout and kidney disease. Financially, it has no sales, ongoing losses, a thin balance sheet, and depends heavily on external funding, with reverse splits hinting at historical share price pressure and dilution. Strategically, it has some meaningful assets: proprietary formulation technology, patent coverage, orphan drug status, and a focus on patients poorly served by current treatments. The company’s future will largely be determined by clinical trial outcomes, regulatory decisions, and its ability to secure partners or capital; until then, the investment case is driven far more by pipeline prospects than by current financial performance.

NEWS

October 21, 2025 · 8:00 AM UTC

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

Read more

October 20, 2025 · 8:34 PM UTC

XORTX Issues Correction Notice and XORTX Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Deficiency

Read more

October 20, 2025 · 6:45 PM UTC

XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency

Read more

October 17, 2025 · 7:00 AM UTC

XORTX Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems

Read more

September 3, 2025 · 7:00 AM UTC

XORTX Initiates IND Preparation for XORLO™ in Gout Program

Read more